You Haoming, Li Sitong, Guo Xueyuan, Jiang Chao, Zhou Lu, He Liu, Wang Wei, Li Songnan, Tang Ribo, Liu Nian, Jiang Chenxi, Yu Ronghui, Zhou Ning, Sang Caihua, Long Deyong, Du Xin, Ma Changsheng, Dong Jianzeng
Department of Cardiology, National Clinical Research Centre for Cardiovascular Diseases, Beijing Anzhen Hospital, Capital Medical University, Beijing Advanced Innovation Center for Big Data-Based Precision Medicine for Cardiovascular Diseases, Beijing, China.
Heart Health Research Center (HHRC), Beijing, China.
Pacing Clin Electrophysiol. 2025 May;48(5):529-537. doi: 10.1111/pace.15181. Epub 2025 Apr 2.
The effectiveness of continuous anti-arrhythmic drugs (AAD) therapy during the 3-month blanking period following repeat catheter ablation to prevent atrial fibrillation (AF) recurrence remains unclear. To evaluate the impact of continuous AAD therapy during the blanking period on AF recurrence in patients with paroxysmal atrial fibrillation (PAF) undergoing repeat ablation.
Patients with PAF who underwent repeat ablation from the China-AF Registry (2011-2022) were included in this study and categorized into two groups based on AAD use during the 3-month blanking period. The AF recurrence was defined as recurrent atrial tachyarrhythmias lasting for >30 s following the blanking period. Cox proportional hazard models were performed to assess the association between AAD status in the blanking period and AF recurrence at 12 months.
The study included 740 PAF patients (mean age 59.4 ± 10.6 years, 36.1% female) who underwent repeat ablation, with 289 patients in the on-AAD group and 451 in the off-AAD group. At 12 months post-ablation, 258 patients (34.9%) experienced AF recurrence. After adjusting for confounders, AAD use during the blanking period did not significantly associate with AF recurrence within 12 months after this period (HR = 1.07; 95% CI: 0.83-1.37; p = 0.599). Consistent results were found in different age, sex, body mass index, left atrial diameter, and CHADS-VASc score subgroups.
There was no significant relationship between AAD therapy during the blanking period after repeat ablation and AF recurrence at 12 months in patients with PAF.
在重复导管消融术后3个月的空白期内，持续抗心律失常药物（AAD）治疗预防心房颤动（AF）复发的有效性尚不清楚。旨在评估空白期持续AAD治疗对阵发性心房颤动（PAF）患者重复消融术后AF复发的影响。
本研究纳入了中国房颤注册研究（2011 - 2022年）中接受重复消融的PAF患者，并根据3个月空白期内AAD的使用情况分为两组。AF复发定义为空白期后持续超过30秒的复发性房性快速心律失常。采用Cox比例风险模型评估空白期AAD使用状态与12个月时AF复发之间的关联。
该研究纳入了740例接受重复消融的PAF患者（平均年龄59.4±10.6岁，女性占36.1%），其中AAD治疗组289例，未使用AAD组451例。消融术后12个月，258例患者（34.9%）出现AF复发。在调整混杂因素后，空白期使用AAD与该时期后12个月内AF复发无显著相关性（HR = 1.07；95%CI：0.83 - 1.37；p = 0.599）。在不同年龄、性别、体重指数、左心房直径和CHADS - VASc评分亚组中发现了一致的结果。
PAF患者重复消融术后空白期的AAD治疗与12个月时AF复发之间无显著关系。
